Last reviewed · How we verify
BT-KTM-I
BT-KTM-I is a small molecule that targets the PDE3 enzyme.
BT-KTM-I is a small molecule that targets the PDE3 enzyme. Used for Acute heart failure.
At a glance
| Generic name | BT-KTM-I |
|---|---|
| Also known as | Esketamine |
| Sponsor | Chengdu Brilliant Pharmaceutical Co., Ltd. |
| Drug class | PDE3 inhibitor |
| Target | PDE3 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PDE3, BT-KTM-I increases the levels of cyclic AMP, leading to vasodilation and improved cardiac function.
Approved indications
- Acute heart failure
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT-KTM-I CI brief — competitive landscape report
- BT-KTM-I updates RSS · CI watch RSS
- Chengdu Brilliant Pharmaceutical Co., Ltd. portfolio CI